TROG Cancer Research
Members Login   CQMS Login

ANROTAT

Title

Assessment of New Radiation Oncology Technologies and Treatments (TRP 11.A)

Summary

This study will help researchers find out the differences between existing and new types of radiation therapy treatment methods that are being used to treat cancer patients in Australia.

Researchers collected information from patients about their treatment, their individual experience, and costs associated with their treatment to compare existing and new types of radiation therapy treatment methods currently available in Australian Treatment Centres.

The ultimate aim of this study is to make the most effective radiation therapy treatment methods available to all cancer patients in Australia.

Accrual

120

Study chairperson

Prof Gill Duchesne, Peter MacCallum Cancer Centre, VIC

Study contact

Rebecca Montgomery
Phone: 02 4014 3910
Email: Rebecca.montgomery@trog.com.au

Reports

ANROTAT Final Reports (32mB, .zip file)

Further information

ANROTAT on Australian Cancer Trials Register


Brain & Central Nervous System

 08.05 WBRT

Hong A; Hallock H; Valenzuela M; Lo S;  Paton E; Ng D; Dhillon H; Jacobsen K; Reisse C; Fogarty G. Hippocampal avoidance whole brain radiation therapy is associated with preservation of hippocampal volume at six months: a case series. Neurooncol Open Access 2017 Mar; 1:1.
DOI: 10.21767/2572-0376.100017

 08.05 

 WBRT  

Fogarty G, Hong A, Dolven-Jacobsen K, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson J. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes 2015 May; 8(192).
DOI: 10.1186/s13104-015-1153-5

08.02 GBM

Perry J, Laperriere N, O'Callaghan C, Brandes A, Menten J, Phillips C, Fay m, Nishikava R, Carncross J, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Goldinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-course radiation plus temozolomide in elderly patients with glioblastoma. New Engl J Med. 2017 Mar; 376(11):1027-37.
DOI: 10.1056/NEJMoa1611977

06.01 -

Baumert B, Hegi M, Van Den Bent J, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes A, Kantor G, Taphoorn M, Ben Hassel M, Hartmann C, Ryan G, Capper D, Kros J, Kurscheild S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg J, Feuvret L, Reijneveld J, Chinot O, Gijtenbeek J, Rossiter J, Dif N, Balana C, Barvo-Marques J, Clement P, Marosi C, Tzuk-Shina T, Nordal R, Rees J, Lacombe D, Mason W, Stupp R.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1521-32.
DOI: 10.1016/S1470-2045(16)30313-8

06.01

-

Reijneveld J, Taphoorn M, Coens C, Bromber J, Mason W, Hoang-Xuan K, Ryan G, Beh Assel M, Enting R, Brandes A, Wick A, CHinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulous V, Gorlia T, Bottomley A, Stupp R, Baumert B. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1533-42.
DOI: 10.1016/S1470-2045(16)30305-9

98.05 -

Roos D, Wirth A, Burmeister B, Spry N, Drummond K, Beresford J and McClure B. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol. 2006 Sep; 80(3):318-22.
DOI: 10.1016/j.radonc.2006.08.004

Back to top


Breast

11.01  SUPREMO 

Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron D, Bartlett J, Bowman A, Piper T, Cunningham C, Canney P, Kunkler I. The BIG 2.04 MRC/EORTC  SUPREMO Trial - Pathology quality assurance of a large phase 3 randomised international clinical trial of post mastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Res Treat. 2017 Feb; 163(1):63-9.
DOI: 10.1007/s10549-017-4145-4

 10.02 

 RAPID  

Peterson DJ, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim D-H, Kong I, Germain I, Nichol A, Akra M, Roy I, Reed M, Fyles A, Trotter T, Perera F, Balkwill S, Lavertu S, Elliott E, Julian JA, Levine MN, Whelan TJ.  Predictors of adverse cosmetic outcome in the RAPID trial: An exploratory analysis. Int J Radiat Oncol Biol Phys. 2015 Apr; 91(5):968-76.

10.02

RAPID

Olivotto  IA, Whelan  TJ, Parpia S, Kim DH, Berrang T, Truong  PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. J Clin Oncol. 2013 Nov; 31(32):4038-45. 

06.02

APBI

Kron T, Willis D, Link E, Lehman M, Campbell G, O’Brien P and Chua B. Can we predict plan quality for external beam partial breast irradiation: Results of a multicenter feasibility study (Trans Tasman Radiation Oncology Group Study 06.02). Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):817-824.

06.02

APBI

Kron T, Willis D, Bignell F, Martland J, Donnell S, May S, Chua BH. Centre credentialing for Trans Tasman Radiation Oncology Group trial 06.02: multicentre feasibility study of accelerated partial breast irradiation. J Med Imag Radiat Oncol. 2009 Aug; 53(4):412–18.

06.02

APBI

Kron T, Willis D, Miller J, Hubbard P, Oliver M, Chua B. A spreadsheet to determine the volume ratio for target and breast in partial breast irradiation. Australas Phys Eng Sci Med. 2009 Jun; 32(2):98-104.
 

03.05

MA20

Whelan T.J, Olivotto I, Parulekar W, Ackerman I, Chua B, Nabid A, Vallis K, White J, Rousseau P, Fortin A, Pierce L, Manchul L, Chafe S, Nolan M, Craighead P, Bowen J, McCready D, Pritchard K, Gelmon K, Murray Y, Chapman J, Chen B, Levine, M. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015 Jul; 373(4):307-16. 

89.02

-

Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol. 1999 May; 43(2):220-26. 

89.02

-

Christie DRH, O'Brien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS et al. A comparison of methods of cosmetic assessment in breast conservation treatment. Breast. 1996 Oct; 5(5):358-67

89.02

-

Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int J Radiat Oncol Biol Phys. 1995 Jan; 31(2): 305-13. 
 

Back to top


Gastrointestinal

08.08  TOPGEAR 

Leong T, Smithers M, Haustermans K, Michael M, Gebski V, Miller D, Simes J, Zalcberg J, Boussioutas A, Findlay M, O'Connell R, Verghis J, Willis D, Kron T, Crain M, Murray W, Lordick F, Swallow C, Darling G, Wong R. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG (formerly NCIC CTG). Ann Surg Oncol. 2017 Aug; 24(8): 2252-58
DOI: 10.1245/s10434-017-5830-6

03.02

 - 

Leong T, Lim Joon D, Willis D, Jayamoham J, Spry N, Harvey J, Di lulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-fluorouracil before and after three-dimensional Conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation Oncology group. Int J Radiat Oncol Biol Phys. 2011 Mar; 79(3):690-95.

01.04  -

McLachlan S, Fisher R, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland S, McKendrick J, McClure B, Mackay J, Ngan S. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar; 55:15-26

01.04

-

Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D, Ackland S, Schache D, McClure B, McLachlan S, McKendrick J, Leong T, Hartopeanu C, Zalcberg and Mackay J. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer (TROG01.04). J Clin Oncol. 2012 Nov; 30(31):3827-33.

99.02

-

 Matthews J, Burmeister B, Borg M, Capp A, Joseph D, Thompson KM, Thompson PI, Harvey JA, Spry NA. T1-2 anal carcinoma requires elective inguinal radiation treatment- the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol. 2011 Jan; 98(1):93-98.

98.01

-

Ngan SYK, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D. Promising results of a co-operative group phase II trials of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum. 2005 Jul; 48(7):1389-96.

 98.01 

-

Ngan SYK, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, MacKay JR, Joseph D, Bell A and Goldstein D. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001 Jul; 50(4):883-87. 

96.02

-

Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. J Clin Oncol. 2003 May; 15(3): 98–108.

96.02

-

Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P and Spry N. Causes for increased myelosuppression with increasing age in patients with esophageal cancer treated by chemo-radiation. Eur J Cancer. 1999 Jun; 35(6):921-27. 
 

94.01

-

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep; 6(9):659-68.

89.04

-

Burmeister BH, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the oesophagus: current status and future directions. Med J Aust. 1997 Oct; 167(7):349-50.

89.04

-

Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg. 1997 Jun; 23(3):219-23.

89.04

-

Denham J and on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Response to L. R. Coia re factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1997 Jan; 42(1): 91-2. (Letter)

89.04

-

MacKean J, Burmeister BH, Lamb DS, Denham JW. Concurrent chemo-radiation for oesophageal cancer - Factors influencing myelotoxicity. Australas Radiol. 1996 Nov; 40(4):424-29.

89.04

-

Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1996 Jul; 40(1):31-4

89.04

-

Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicentre study. Int J Radiat Oncol Biol Phys. 1995 Jul; 32(4):997-1006. 

89.04

-

Denham JW. Oesophageal cancer - guarded optimism. Med J Aust. 1994 Jun; 160(11):669-70. 

89.03

-

Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. 

Back to top


Gynaecological

 08.04  PORTEC-3

Jameson M, Mcnamara J, Bailey M, Metcalfe P, Holloway L, Foo K, Do V, Mileshkin L, Creutzberg, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imag Radia Oncol.  2016 Sep; 60(4):554-59
DOI: 10.1111/1754-9485.12447

 08.04 

PORTEC-3  

de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial, for the PORTEC study group. Lancet Oncol. 2016 Jul; 17(8):1114-26 
DOI: 10.1016/S1470-2045(16)30120-6

Back to top


Head & Neck

 12.03 

 EAT 

Beck A, Baker A, Britton B, Wratten C, Bauer J, Wolfenden L, Carter G. Fidelity considerations in translational research: Eating As Treatment - a stepped wedge, randomised controlled trial of a dietitian delivered behaviour change counselling intervention for head and neck cancer patients undergoing radiotherapy. TRIALS. 2015 Oct; 16:465. 

12.03

EAT 

Britton B, McCarter K, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McElduff P, Halpin S, Carter G. Eating As Treatment (EAT) study protocol: a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy. BMJ Open. 2015 Jul; 5(7):e008921.

07.04 CETUXIMAB 

Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4);948-54.
DOI: 10.1016/j.ijrobp.2017.02.088

07.03 RadioHUM

Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncology. 2017 Dec; 75:75-80.
DOI: 10.1016/j.oraloncology.2017.10.021

07.03

 RadioHUM 

Macann A, Fua  T, Milross C, Porceddu S, Penniment  M, Wratten C, Krawitz H, Poulsen M, Tang CI, Morton RP, Hay KD, Thomson V, Bell ML, King MT, Fraser-Browne CL, Hockey HP. Phase III trial of domiciliary humidification to mitigate acute mucosal toxicity during radiotherapy for head and neck cancer: First report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study. Int J Radiat Oncol Biol Phys. 2014 Mar; 88(3):572-79

02.02  HeadSTART 

Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar; 97(4): 678-86. 
DOI: 10.1016/j.ijrobp.2016.03.017

02.02

 HeadSTART 

Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T. Radiotherapy Protocol Deviations and Clinical Oucomes: A Meta-Analysis of Cooperative Group Clinical Trials. J Natl Cancer Inst. 2013 Mar; 105(6):387-93.

02.02

 HeadSTART 

Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol. 2012 Aug; 48(8):689-702.  

02.02

 HeadSTART 

Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O’Sullivan B, Giacia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without Tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 2012 Jun; 18(6):1798-807.

02.02

 HeadSTART 

Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Prognostic significance of Plasma Osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012 Jan; 18(1):301-07. 

02.02

 HeadSTART 

Young R, Rischin D; Fisher R; et al. Relationship between Epidermal Growth Factor Receptor Status, p16(INK4A), and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Biomar Prev. 2011 Jun; 20(6):1230-37. 

02.02

 HeadSTART 

Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA. Prognostic Significance of p16INK4A and Human Papillomavirus in patients with Oropharyngeal Cancer Treated on TROG 02.02 Phase III trial. J Clin Oncol. 2010 Sep; 28(27):4142-48.

02.02

 HeadSTART 

Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. J Clin Oncol. 2010 Jun; 28(18):2996-3001.

02.02

 HeadSTART 

Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun; 28(18):2989-95.

98.02

-

Corry J, Peters L, Fisher R, Macann A, Jackson M, McClure B, Rischin D. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02. Head Neck. 2008 Jun; 30(6):737-42.   

98.02

-

Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S and Peters LJ. Prognostic significance of [F-18]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol. 2006 May; 24(13):2098-04.

98.02

-

Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005 Jan; 23(1):79-87. 

91.01

-

Daly T, Poulsen GM, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003 Aug; 68(2): 113–22.

91.01

-

Denham JW and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys. 2001 Nov; 51(3): 807–19.

91.01

-

Poulsen M, Denham J, Peters L, Lamb D, Spry NA, Hindley A, Krawitz, H Hamilton C, Keller J, Tripcony L, Walker Q. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91.01). Radiother Oncol. 2001 Aug; 60(2):113-22. 

91.01

-

Poulsen M, Denham JW, Spry N, Lamb D, Peters L, Williamson S and L Tripcony. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Acute toxicity analysis of a phase III randomised trial of accelerated. Australas Radiol. 1999 Nov; 43(4):487-94. 

91.01

-

Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O'Brien P, Spry NA, Penniment  M, Krawitz H, Williamson  S,  Bear J,  Tripcony  L. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999 Aug; 52(2):157-64. 

91.01

-

Hamilton CS, Walker Q, Poulsen M, Spry N, Lamb D, Denham JW and Steigler A. Quality Assurance Audit in an Australasian Phase III Trial of Accelerated Radiotherapy for Head and Neck Cancer (TROG 91. 01). Australas Radiol. 1999 May; 43(2):227-32. 

89.03 - Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. 

Back to top


Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4);948-54.
DOI: 10.1016/j.ijrobp.2017.02.088

Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncology. 2017 Dec; 75:75-80.
DOI: 10.1016/j.oraloncology.2017.10.021

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.